Companies › Agios Pharmaceuticals
4 active drug programs in 15 registered trials: 7 Phase 3, 5 Phase 2, 3 Phase 1; Hematology, Metabolic and endocrine, Other; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mitapivat Pyruvate kinase isozymes R/L activator | PKLR | Phase 3 | Non-Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Alpha-Thalassemia; Pediatric Pyruvate Kinase Deficiency; Sickle Cell Disease … | Dec 2028 |
| Tebapivat (AG-946) | – | Phase 2 | Sickle Cell Disease; Myelodysplastic Syndromes | May 2027 |
| AG-181 Phenylalanine hydroxylase (PAH) activator | PAH | Phase 1 | Phenylketonuria | Jan 2028 |
| AG-236 | – | Phase 1 | Healthy Participants | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07075640 | AG-236 | Phase 1 | Healthy Participants | Other | Feb 2026 |
| NCT06924970 | Tebapivat (AG-946) | Phase 2 | Sickle Cell Disease | Hematology | May 2027 |
| NCT07241234 | AG-181 | Phase 1 | Phenylketonuria | Metabolic and endocrine | Jan 2028 |
| NCT04610866 | Mitapivat | Phase 1 | Sickle Cell Disease | Hematology | Feb 2028 |
| NCT04770753 | Mitapivat | Phase 3 | Non-Transfusion-dependent Alpha-Thalassemia | Hematology | Dec 2028 |
| NCT07517133 | Mitapivat | Phase 3 | Non-Transfusion-dependent Alpha-Thalassemia | Hematology | Mar 2029 |
| NCT05490446 | Tebapivat (AG-946) | Phase 2 | Myelodysplastic Syndromes | Hematology | Mar 2029 |
| NCT04770779 | Mitapivat | Phase 3 | Transfusion-dependent Alpha-Thalassemia | Hematology | Jun 2029 |
| NCT07506863 | Mitapivat | Phase 3 | Transfusion-dependent Alpha-Thalassemia | Hematology | Jun 2029 |
| NCT05144256 | Mitapivat | Phase 3 | Pediatric Pyruvate Kinase Deficiency | Hematology | Jun 2029 |
| NCT07656415 | Mitapivat | Phase 3 | Sickle Cell Disease | Hematology | Aug 2029 |
| NCT07055243 | Mitapivat | Phase 2 | Anemia | Hematology | Oct 2029 |
| NCT05175105 | Mitapivat | Phase 3 | Pediatric Pyruvate Kinase Deficiency | Hematology | Jan 2030 |
| NCT05031780 | Mitapivat | Phase 2 | Sickle Cell Disease | Hematology | Feb 2030 |
| NCT03692052 | Mitapivat | Phase 2 | Thalassemia | Hematology | Sep 2030 |
Cash and short-term investments of $907m on 2026-09-30; operating cash outflow about $316m a year; runway about 34 months at that burn, to Aug 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
BioMarin Pharmaceutical Forma Therapeutics ScinnoHub Pharmaceutical Novo Nordisk PTC Therapeutics Chongqing Peg-Bio Biopharm NGGT NGGT (Suzhou) Biotechnology
ScinnoHub Pharmaceutical Forma Therapeutics X4 Pharmaceuticals Nanjing Chia-tai Tianqing Pharmaceutical OPKO Health
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.